Investor Overview
KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal co...
Stock Information
NASDAQ CM$12.39NEWS
Kindred Biosciences Announces Third Quarter 2018 Financial Results
November 7, 2018
SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: K...
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent
October 30, 2018
- Statistically significant reduction in pruritus versus placebo was achieved ac...
Kindred Biosciences to Announce Third Quarter 2018 Financial Results
October 24, 2018
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m...